Leading edge medical techniques greatly contribute to the health and welfare of humanity, but there are many challenges yet to be resolved.
Organ transplantation is an effective medical technique to save end-stage organ failure patients, but suffers from the fundamental problem of relying on the availability of organ donors. In contrast, regenerative medicine aims to artificially create the necessary organs and tissues, but it is an extremely difficult challenge against nature to create organs and tissues of complex function and structure by in vitro culture technology. Efforts are underway in the field of regenerative medicine to use pluripotent stem cells such as iPS and ES cells to restore functionally impaired organs and tissue. Needless to say the efficacy and safety of the stem cell therapies must be guaranteed. In addition, assisted reproductive technology, which has advanced remarkably in recent years, is advancing into the areas of the creation of sperm and eggs and genetic manipulation of the embryo, where a keen insight into the mission and nature of scientific technologies is essential.
Against this background, translational research using large animals can be considered essential for the development of leading edge techniques such as organ transplantation, regenerative medicine and assisted reproductive technologies. Translational research is empirical research that bridges the results of basic research to clinical application.
Meiji University International Institute for Bio-Resource Research is advancing translational research relating to leading edge medicine, making full use of cloned pigs and genetically modified pigs that we have developed as unique large experimental animals. It is our aim to contribute to the realization of tomorrow's medicine through translational research using our platform of high value-added pigs.
Dr. Hiroshi Nagashima
Professor at the Laboratory of Medical Bioengineering, Department of Life Sciences, School of Agriculture